证券代码： 002020 证券简称：京新药业 编号：2018002 浙江京新药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 广发证券吴文华、国投瑞银王鹏、前海人寿王安艺、基石资 | | 人员姓名 | 本朱筱姗 | | | 时间 | 2018 年 11 月 6 | 日 | | 地点 | | 浙江京新药股份有限公司新昌总部行政楼会议室 | | 上市公司接待人 员 | | 董事会秘书金志平、证券事务代表张波 | | 投资者关系活动 | 1 | 、介绍公司基本业务情况和未来发展规划。 | ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-----------------------|-------------------------------|---------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | 循远投资覃婷；广发资管徐默凡；海通自营胡幸；恒远资本李 | | 参与单位名称及 | | 婧；歌斐资产沈芃泽；野村资管张熙；圆信永丰方瑾；国泰君 安李子波；华泰资管李勇剑；凯石吴蔽野；兴业证券胡储辉； | | 人员姓名 | | 国信证券资管隋欣；东海自营施杨扬；国泰基金邱晓旭；中融 ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |-------------------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | 兴业证券胡储辉、林莹，财通证券华挺，东吴证券于彦秋，博 道基金邓韵阳，中航信托谢天，深圳国诚投资张妃珺、相健、 | | | | | | 参与单位名称及 人员姓名 | 杨海 ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-----------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | 中航信托戴佳敏，泰康资产王晓峰，观富（北京）资产杨洁， | | | | 光大资产徐德仁，富国基金姜恩铸，新疆前海联合基金张宇煊， | | | | ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | --- | --- | |----------------|-------------|-------------------------------------|------------------------------|--------|-------|---------------------| | | | | | | | | | | | √特定对象调研 □分析师会议 | | | | | | | | □媒体采访 □业绩说明会 | | | | | | 投资者关系活动 | □新闻发布会 | | □路演活动 | | | | | 类别 | □现场参观 | | | | | | | | □其他 | （请文字说明其他活动内容） | | | | | | | | 闫庚威 太平基金 许睿 富安达 | | | | | | | | 方瑾 圆信永丰 鲍冲 中信建投资管 | | | | | | | | | | | | | | | | 邱晓旭 兴全基金 ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 927.29 million, an increase of 11.01% compared to CNY 835.31 million in the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was CNY 174.70 million, reflecting a growth of 9.66% from CNY 159.31 million year-on-year[6]. - The net cash flow from operating activities for the year-to-date period was CNY 446.51 million, up 16.46% from CNY 384.99 million in the previous year[6]. - The company's basic earnings per share remained stable at CNY 0.20, with a diluted earnings per share also at CNY 0.20[6]. - The company reported a net profit margin improvement, with net profit for the period increasing due to higher revenue and controlled costs[25]. - The net profit for the current period is 475,470,952.50, an increase from 440,185,520.85 in the previous period, representing a growth of approximately 8%[27]. - Operating profit for the current period is 533,943,335.85, compared to 486,661,837.14 in the previous period, indicating an increase of about 10%[27]. - The total profit for the current period is 532,781,444.69, compared to 488,259,200.58 in the previous period, indicating an increase of about 9%[27]. Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 7,013.43 million, representing a 5.98% increase from CNY 6,617.70 million at the end of the previous year[6]. - The company's total liabilities reached ¥2,021,985,295.16, up from ¥1,639,127,704.24, reflecting an increase of 23.4%[22]. - The total equity attributable to shareholders was CNY 4,967.43 million, showing a slight increase of 0.18% from CNY 4,958.33 million in the previous year[6]. - The total equity attributable to shareholders was ¥4,967,428,026.10, a slight increase from ¥4,958,326,790.13[24]. Cash Flow - The net cash flow from operating activities surged by 382.27% to ¥681,416,066.30, driven by increased sales revenue and improved collection of accounts receivable[11]. - Cash flow from operating activities for the current period is 681,416,066.30, significantly up from 141,293,758.40 in the previous period, showing a substantial improvement[31]. - The net cash flow from investing activities is -617,421,539.09, a decrease from 277,295,528.25 in the previous period, indicating a negative trend[31]. - The net cash flow from financing activities is -181,848,325.22, compared to 81,552,926.87 in the previous period, reflecting a decline[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,299[15]. - The largest shareholder, Lü Gang, holds 20.77% of the shares, totaling 178,796,755 shares[15]. Operating Costs and Expenses - Total operating costs for the third quarter of 2022 were ¥2,300,367,857.99, up from ¥2,124,942,041.95, reflecting a year-over-year increase of 8.3%[25]. - Research and development expenses for the third quarter of 2022 amounted to ¥246,403,668.53, compared to ¥227,892,721.46 in the previous year, indicating an increase of 8.1%[25]. - The company's financial expenses decreased by 125.93% to -¥59,376,378.44, mainly due to increased interest income from time deposits and exchange gains[11]. - The company reported a 746.30% increase in non-operating expenses to ¥2,179,982.31, primarily due to an increase in bad debt write-offs[11]. Asset Composition - Current assets totaled ¥3,271,012,226.99 as of September 30, 2022, slightly down from ¥3,292,888,604.35 at the end of the previous year[22]. - Non-current assets increased to ¥3,742,419,718.96 from ¥3,324,808,506.47, marking a significant rise of 12.5%[22]. - Cash and cash equivalents decreased to ¥1,543,092,081.54 from ¥1,558,668,597.33, a decline of 1%[22]. - Cash and cash equivalents at the end of the period amount to 1,401,844,562.75, slightly up from 1,391,803,166.97 in the previous period[31].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.87 billion, representing an increase of 8.46% compared to the same period last year[22]. - Net profit attributable to shareholders was approximately ¥274.93 million, an increase of 15.68% year-on-year[22]. - The net cash flow from operating activities reached approximately ¥274.03 million, a significant increase of 306.81% compared to the previous year[22]. - Total assets at the end of the reporting period were approximately ¥6.71 billion, reflecting a growth of 1.33% from the end of the previous year[22]. - The net assets attributable to shareholders decreased by 3.41% to approximately ¥4.79 billion compared to the end of the previous year[22]. - Basic and diluted earnings per share remained stable at ¥0.35, unchanged from the previous year[22]. - The weighted average return on equity was 6.09%, down by 0.79 percentage points compared to the previous year[22]. - The company reported non-recurring gains and losses amounting to approximately ¥22.12 million, primarily from government subsidies and asset disposals[29]. - The company achieved operating revenue of 1.873 billion yuan, a year-on-year increase of 8.46%[59]. - The company's net profit attributable to shareholders reached 297 million yuan, up 6.19% year-on-year, while the net profit after deducting non-recurring gains and losses was 275 million yuan, an increase of 15.68%[59]. - The medical device segment reported revenue of 297 million yuan, reflecting a significant year-on-year growth of 19.10%[59]. Market and Product Development - The company is focused on expanding its market presence and developing new products and technologies to drive future growth[33]. - The product structure has been continuously optimized, with stable growth in the profitability of main businesses, including cardiovascular drugs and CNS drugs, with key products like Levetiracetam tablets ranking first in the national hospital market[46]. - The company has a rich product pipeline covering CNS, cardiovascular, and digestive systems, with over 10 innovative drug projects in progress[48]. - The company aims to become a leader in the CNS and cardiovascular fields, continuously enhancing its core competitiveness through innovation and collaboration[46]. - The company has established a comprehensive marketing network covering commercial channels, retail pharmacies, and hospitals, enhancing its brand recognition and market influence[53]. - The e-commerce sales channel grew rapidly, achieving revenue of 78.48 million yuan, a remarkable year-on-year increase of 370%[64]. - The company is actively developing new medical display technologies and has entered into strategic partnerships with major players like Siemens and Fujifilm[65]. Research and Development - The company holds a total of 204 patents, including 149 invention patents, showcasing its strong R&D capabilities[52]. - The company plans to establish a new R&D platform in Hangzhou focusing on biopharmaceuticals and medical devices, further enhancing its innovation capabilities[52]. - The R&D investment for the reporting period was ¥170,157,604.98, reflecting a 7.94% increase from ¥157,644,108.74 in the previous year[76]. - The company has submitted a drug registration application for the innovative drug EVT201, which, if approved, will enhance its competitiveness in the mental health sector[71]. - The company is focused on building a research team that aligns with its innovative transformation goals to enhance its competitive edge in the pharmaceutical industry[110]. Operational Efficiency - The pharmaceutical manufacturing segment generated ¥1,572,666,202.34 in revenue, accounting for 83.98% of total revenue, with a year-on-year growth of 6.74%[79]. - The company has implemented 84 lean management projects in drug manufacturing, resulting in an 8.3% increase in per capita production efficiency[69]. - The company has adopted a procurement model combining centralized procurement and subsidiary self-procurement to ensure quality and cost control[38]. - The production model is based on sales forecasts, maintaining appropriate safety stock, and customized production for EU exports[39]. - The company has signed strategic cooperation agreements with key suppliers to ensure the continuity and stability of the supply chain[38]. Environmental and Social Responsibility - Environmental regulations are becoming stricter, and the company is committed to sustainable development by adhering to higher environmental standards in its manufacturing processes[110]. - The company has established a comprehensive wastewater treatment system with a daily processing capacity of 1,600 tons, ensuring compliance with discharge standards[126]. - The company has constructed two standard solid waste storage facilities covering an area of approximately 1,800 m² for hazardous waste disposal[126]. - The company has implemented a multi-level condensation and RTO system for treating process waste gases, achieving compliance with emission standards[131]. - The company has invested 10 million yuan to establish a rural revitalization and poverty alleviation fund in collaboration with local enterprises[142]. - The company has successfully passed 13 environmental impact assessments since 2004, demonstrating its commitment to environmental compliance[134]. - The company has installed online monitoring equipment for key wastewater discharge parameters, ensuring real-time compliance tracking[132]. - The company has developed emergency response plans for environmental incidents, enhancing its management capabilities[137]. - The company has achieved stable operation of pollution control facilities, with no reported environmental pollution incidents[130]. - The company has adopted innovative management practices and technological advancements to promote clean production and pollution prevention[131]. Corporate Governance and Shareholder Information - The company has committed to avoid related party transactions with Jingxin Pharmaceutical and Shenzhen Jufeng, ensuring fair pricing and compliance with legal requirements[146]. - The company has pledged that the funds raised from the non-public offering of A-shares in 2020 will be used specifically for project construction and will not be diverted for other purposes[148]. - The company reported no significant litigation or arbitration matters during the reporting period[155]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[151]. - The company has established a special account to manage the funds raised from the non-public offering, ensuring proper usage[148]. - The company has confirmed that all commitments made during the IPO and refinancing processes are being fulfilled normally[148]. - The company has not reported any major related party transactions during the reporting period[157]. - The largest shareholder, Lü Gang, holds 19.75% of the shares, totaling 178,796,755 shares[186]. - The second largest shareholder, Jingxin Holdings Group Co., Ltd., owns 14.91% of the shares, amounting to 134,966,393 shares[190]. - The company has a total of 44,289,798 shares in its repurchase account, representing 4.89% of the total share capital[190]. - There were no changes in the shareholding of directors, supervisors, and senior management during the reporting period[195]. - The controlling shareholder and actual controller of the company did not change during the reporting period[196]. - The company does not have any preferred shares in the reporting period[200].

Financial Performance - The company's operating revenue for Q1 2022 was ¥870,570,379.68, representing a 1.52% increase compared to the previous year[5] - Net profit attributable to shareholders was ¥137,264,079.65, a 2.43% increase from the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥128,283,249.09, showing a significant increase of 23.12% year-on-year[5] - The net cash flow from operating activities reached ¥169,274,493.96, marking a substantial increase of 112.99% compared to the same period last year[5] - Total operating revenue for the current period reached ¥870,570,379.68, an increase of 1.23% compared to ¥857,514,892.19 in the previous period[27] - Net profit for the current period was ¥137,868,319.80, representing a 3.03% increase from ¥133,724,238.90 in the previous period[30] - The company reported a total comprehensive income of ¥138,090,753.91 for the current period, compared to ¥133,866,768.02 in the previous period[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,573,665,520.18, a decrease of 0.67% from the end of the previous year[7] - Total current assets decreased to ¥3,144,265,135.57 from ¥3,292,888,604.35[21] - Total non-current assets increased to ¥3,429,400,384.61 from ¥3,324,808,506.47[21] - Total liabilities amounted to ¥1,661,055,359.69, an increase from ¥1,639,127,704.24 in the previous period[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 46,641[14] - The largest shareholder, Lü Gang, holds 19.75% of shares, totaling 178,796,755 shares[14] - The equity attributable to shareholders was ¥4,890,800,998.04, down 1.36% from the previous year[7] - Total equity attributable to shareholders of the parent company was ¥4,890,800,998.04, a slight decrease from ¥4,958,326,790.13 in the previous period[24] Cash Flow - The company's cash and cash equivalents amount to ¥1,655,392,033.88, an increase from ¥1,558,668,597.33[18] - The cash received from operating activities was $879,444,379.12, down from $970,225,907.96, showing a decline in operational cash generation[34] - The total cash outflow from operating activities was $710,169,885.16, compared to $890,749,958.52 in the previous period, indicating a reduction in cash outflows[34] - Cash inflow from financing activities totaled $950,000.00, a decrease from $24,117,182.36 in the previous period, indicating reduced financing activity[37] - The net cash flow from financing activities was $884,532.86, a significant improvement from -$179,637,569.17 in the previous period, suggesting better management of financing[37] Operational Efficiency - The company reported a decrease in basic and diluted earnings per share to ¥0.16, a decline of 5.88% compared to the previous year[5] - The weighted average return on equity was 2.85%, down 0.49 percentage points from the previous year[5] - Total operating costs decreased to ¥725,127,219.20, down 1.65% from ¥739,345,608.91 in the previous period[27] - Research and development expenses for the current period were ¥79,224,664.20, up from ¥78,428,836.82 in the previous period[27] Investment Performance - The company experienced a 69.19% decrease in trading financial assets, primarily due to a reduction in purchased financial products[9] - The company reported a 40.02% increase in construction in progress, attributed to the addition of new engineering projects[9] - Total cash inflow from investment activities was $458,586,902.49, down from $567,471,397.58, indicating a decrease in investment cash inflows[34] - The net cash flow from investment activities was -$177,508,796.25, compared to a positive $195,167,783.21 in the previous period, showing a negative shift in investment performance[34] - The cash received from investment income was $38,291,284.04, an increase from $17,471,397.58, reflecting improved investment returns[34]

Financial Performance - The company's operating revenue for 2021 was ¥3,335,970,889.11, representing a 2.39% increase compared to ¥3,258,075,481.25 in 2020[22] - The net profit attributable to shareholders for 2021 was ¥614,001,126.25, a decrease of 5.98% from ¥653,070,206.69 in 2020[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 15.49% to ¥515,377,939.98 in 2021 from ¥446,243,001.41 in 2020[22] - The net cash flow from operating activities decreased by 28.87% to ¥365,024,284.78 in 2021 from ¥513,210,535.56 in 2020[22] - The basic earnings per share for 2021 was ¥0.75, down 8.54% from ¥0.82 in 2020[22] - The total assets at the end of 2021 were ¥6,415,365,229.53, an increase of 13.22% from ¥5,666,246,990.95 at the end of 2020[22] - The weighted average return on net assets for 2021 was 14.37%, a decrease of 3.01 percentage points from 17.38% in 2020[22] - The company's operating income for the fourth quarter was ¥867,803,456.27, with a total annual operating income of ¥3,335,970,889.11, reflecting stable revenue generation[26] - The net profit attributable to shareholders for the fourth quarter was ¥184,791,060.33, showing a consistent increase throughout the year[26] - The net cash flow from operating activities in the fourth quarter reached ¥222,926,490.48, indicating strong cash generation capabilities[26] Assets and Investments - The net assets attributable to shareholders of the listed company increased to ¥4,817,411,307.25, representing a growth of 22.97% compared to ¥3,917,602,965.69 from the previous year[24] - The company reported a significant increase in R&D expenses, totaling ¥329,331,078.76, up 27.04% year-on-year, driven by ongoing innovative drug projects[94] - The company has a total of ¥343,887,358.83 in restricted assets, primarily due to guarantees for bank acceptance bills[115] - The total amount of raised funds used during the reporting period was ¥17,954.53 million, with a cumulative usage of ¥81,039.15 million[120] - The company has a significant focus on generic drug development, aiming to submit over 10 projects annually to strengthen its competitive edge[100] Research and Development - The company invested 329 million yuan in R&D in 2021, a 27% increase year-on-year, focusing on innovative drugs in the CNS and CV fields, with 11 innovative drug projects currently under research[63] - The company has received 29 new invention patents in 2021, bringing the total to 173 patents, including 121 invention patents, showcasing strong R&D capabilities[54] - The company is developing multiple new products, including a modified compound drug for hyperlipidemia and a new anti-epileptic drug, enhancing its product pipeline[100] - The number of R&D personnel rose to 488, an increase of 3.39% from 2020[101] - The company aims to enhance its innovative drug R&D capabilities, targeting the submission of 6 innovative drug applications and bulk R&D submissions for generic drugs in 2022[139] Market and Product Development - The company focuses on the fields of mental health and cardiovascular drugs, with key products including Rosuvastatin and Sertraline, aimed at treating high cholesterol and depression respectively[38] - The company has a diverse product pipeline covering CNS, cardiovascular, and digestive systems, with key products like Levetiracetam ranked first in the hospital market for anti-epileptic drugs[47] - The cardiovascular (CV) segment achieved annual sales revenue of 520 million yuan, with a year-on-year shipment increase of 14% for the CV pipeline[69] - The gastrointestinal (GI) segment reported sales revenue of 466 million yuan, a 15% increase year-on-year, with self-operated business revenue growing by 30%[69] - The company’s internet e-commerce sales exceeded 50 million yuan, marking a 378% year-on-year growth, becoming a new revenue and profit growth point[72] Corporate Governance and Management - The company has a total of nine board members, including three independent directors, ensuring compliance with legal requirements[155] - The company has implemented a transparent performance evaluation and incentive mechanism for its management personnel[159] - The company has a dedicated financial accounting department, ensuring independent financial decision-making and compliance with accounting regulations[170] - The company has a structured organization that operates separately from its controlling shareholder, with no interference in its operational activities[169] - The company actively engages with stakeholders to balance interests and promote sustainable development[160] Strategic Initiatives - The company plans to expand its marketing team to over 1,000 members in 2022 to support the launch of innovative drugs and new products[67] - The company is focusing on expanding its market presence in international mainstream markets, aiming to improve customer structure and increase market share in regions like Europe and North America[143] - The company is committed to enhancing its marketing capabilities through refined management and innovative business models[140] - The company plans to invest 200 million yuan in a new traditional Chinese medicine production base to enhance capacity and upgrade the industry structure[78] - The company has established several subsidiaries, including Hangzhou Jingzhe Biopharmaceutical Technology Co., Ltd. and BEACON & BIGTIDE USA, to enhance its operational capabilities[137] Financial Management - The company achieved a net increase in cash and cash equivalents of ¥626,806,159.85, reflecting a 33.42% increase year-on-year[106] - The company reported a decrease in cash flow from investment activities, with a net cash flow of ¥144,687,969.67, down 68.81% from the previous year[102] - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to 11.7427 million yuan[194] - The chairman, Lü Gang, received a total pre-tax remuneration of 1.6884 million yuan[195] - The company has a unified compensation management system for non-independent directors, supervisors, and senior management based on performance evaluations[193]

Financial Performance - The company's revenue for Q3 2021 was ¥808,255,395.68, representing a 1.64% increase year-over-year[5] - Net profit attributable to shareholders for the same period was ¥158,448,752.24, up 7.34% compared to the previous year[5] - The net profit excluding non-recurring gains and losses increased by 42.75% to ¥146,353,981.33 in Q3 2021[5] - Total operating revenue for the current period reached ¥2,468,167,432.84, a slight increase from ¥2,435,720,765.21 in the previous period, representing a growth of approximately 1.0%[28] - Net profit for the current period was ¥430,347,043.44, up from ¥373,767,202.45, indicating an increase of approximately 15.1%[31] - The company reported a total comprehensive income of ¥430,388,219.79, compared to ¥373,806,112.28 in the previous period, indicating an increase of approximately 15.1%[34] - Earnings per share (EPS) improved to ¥0.54 from ¥0.47, marking a growth of about 14.9%[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,142,610,731.93, an increase of 8.41% from the end of the previous year[7] - As of September 30, 2021, the company's total assets reached CNY 6,142,610,731.93, an increase from CNY 5,666,246,990.95 at the end of 2020[21] - The company's total liabilities decreased to CNY 1,300,441,778.73 from CNY 1,546,858,959.40, a reduction of about 16%[24] - The total liabilities decreased to ¥1,492,681,096.76 from ¥1,733,577,519.82, a reduction of about 13.9%[30] - Total assets increased to $5.69 billion, reflecting a rise of 0.4% from $5.67 billion[44] - Total liabilities amounted to $1,733,577,519.82, a decrease of $25,002,335.04 from the previous period[47] Cash Flow - The company's cash flow from operating activities decreased by 70.33% to ¥142,097,794.30 year-to-date[7] - Cash flow from operating activities was ¥2,468,152,270.44, down from ¥3,020,097,734.74, a decrease of about 18.2%[35] - The net cash flow from operating activities decreased to $142.1 million, down 70.3% from $478.9 million in the previous period[38] - Cash inflow from investment activities totaled $1.26 billion, a decrease of 46.5% compared to $2.34 billion last year[38] - The net cash flow from financing activities improved to $84.6 million, compared to a negative cash flow of $448 million in the same period last year[38] - The total cash and cash equivalents at the end of the period reached $1.39 billion, an increase of 143.4% from $569.8 million at the end of the previous period[38] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,145, with the largest shareholder holding 19.75%[13] - Total equity attributable to shareholders increased to ¥4,630,980,193.06 from ¥3,917,602,965.69, reflecting a growth of approximately 18.2%[30] - Total equity attributable to shareholders reached $3,917,602,965.69, remaining unchanged from the previous period[47] Research and Development - The company has increased its R&D investment to accelerate innovation projects, impacting cash flow[7] - Research and development expenses rose to ¥224,227,329.96 from ¥183,190,418.65, an increase of approximately 22.4%[31] Compliance and Governance - The company has established a three-party supervision agreement for the management of raised funds, ensuring compliance with regulations[20] - The company is actively implementing its fundraising projects as planned, indicating a commitment to growth and expansion[20] - The company has not audited its third-quarter report[48] - The company has implemented new lease standards since 2021, with no retrospective adjustments to prior comparative data[48] Other Financial Metrics - The company's cash and cash equivalents amounted to CNY 1,408,601,265.18, up from CNY 915,349,298.13 in December 2020, reflecting a growth of approximately 53.8%[21] - Accounts receivable increased by 35% to ¥451,898,344.25, attributed to longer collection periods due to the pandemic[9] - Inventory levels rose to CNY 572,134,799.41, compared to CNY 500,755,680.70, indicating an increase of approximately 14.2%[21] - The company reported a significant increase in non-current assets, totaling CNY 2,990,323,277.24, up from CNY 2,541,232,696.18[24] - The company reported a capital reserve of $1,897,451,568.86, unchanged from the previous period[47] - The retained earnings stood at $1,554,590,422.71, remaining stable[47] - Minority interests were recorded at $15,066,505.44, unchanged from the previous period[47]